BSE: 0 | NSE: ONYX | Pharmaceuticals & Drugs |
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Onyx Biotec Ltd is a below average quality company.
The key valuation ratios of Onyx Biotec Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Onyx Biotec Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|
| ROCE % ⓘ | 15.5% | 8.2% | 12.1% | - |
| Value Creation Index ⓘ | 0.1 | -0.4 | -0.1 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | ||||
| Sales ⓘ | 44.9 | 39.5 | 53.8 | 54 |
| Sales YoY Gr. | - | -12% | 36.1% | - |
| Adj EPS ⓘ | 2.8 | 1.6 | 2.3 | 1.7 |
| YoY Gr. | - | -44.7% | 45.2% | - |
| BVPS (₹) ⓘ | 13.9 | 15.4 | 18.7 | 29.9 |
| Adj Net Profit ⓘ | 3.4 | 1.9 | 3 | 3 |
| Cash Flow from Ops. ⓘ | 0.5 | 6.2 | 1.5 | - |
| Debt/CF from Ops. ⓘ | 25.2 | 4.7 | 20.3 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | NA | 36.1% | ||||
| Adj EPS ⓘ | NA | NA | NA | 45.2% | ||||
| BVPSⓘ | NA | NA | NA | 21.1% | ||||
| Share Price | - | - | - | - | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|
| Return on Equity % ⓘ | 20.5 | 10.7 | 14.1 | 6.9 |
| Op. Profit Mgn % ⓘ | 12.9 | 11.4 | 15.5 | NAN |
| Net Profit Mgn % ⓘ | 7.5 | 4.7 | 5.6 | 5.6 |
| Debt to Equity ⓘ | 0.8 | 1.6 | 1.2 | - |
| Working Cap Days ⓘ | 0 | 147 | 154 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 49 | 42 | 0 |
No data to display
Return on Equity has declined versus last 3 years average to 6.90%
Sales growth has been subdued in last 3 years 0.00%
Net Profit has been subdued in last 3 years 0.00%
Debt to equity has increased versus last 3 years average to 1.24
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 1.7 | - |
| TTM Sales (₹ Cr.) | 53.8 | - |
| BVPS (₹.) ⓘ | 29.9 | - |
| Reserves (₹ Cr.) ⓘ | 36 | - |
| P/BV ⓘ | 1.78 | - |
| PE ⓘ | 31.91 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 0.00 / 0.00 |
| All Time Low / High (₹) | - / - |
| Market Cap (₹ Cr.) | 96.7 |
| Equity (₹ Cr.) | 18.1 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 44.3 |
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|
| Sales | 44.86 | 39.48 | 53.75 |
| Operating Expenses ⓘ | 39.09 | 34.99 | 45.42 |
| Manufacturing Costs | 1.42 | 1.12 | 0.99 |
| Material Costs | 26.52 | 21.02 | 35.74 |
| Employee Cost | 8.62 | 10.48 | 6 |
| Other Costs ⓘ | 2.53 | 2.37 | 2.68 |
| Operating Profit ⓘ | 5.77 | 4.49 | 8.33 |
| Operating Profit Margin (%) | 12.9% | 11.4% | 15.5% |
| Other Income ⓘ | 0.12 | 0.12 | 0.13 |
| Interest ⓘ | 0.65 | 0.57 | 2.16 |
| Depreciation ⓘ | 1.45 | 1.49 | 2.25 |
| Exceptional Items ⓘ | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 3.80 | 2.55 | 4.05 |
| Tax ⓘ | 0.44 | 0.70 | 1.02 |
| Profit After Tax | 3.35 | 1.84 | 3.03 |
| PAT Margin (%) | 7.5% | 4.7% | 5.6% |
| Adjusted EPS (₹) | 2.8 | 1.6 | 2.3 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% |
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 16.38 | 18.20 | 24.88 | |||||||
| Share Capital ⓘ | 5.90 | 5.90 | 13.32 | |||||||
| Reserves ⓘ | 10.47 | 12.30 | 11.56 | |||||||
| Minority Interest | 0 | 0 | 0 | |||||||
| Debt | 9.87 | 25.31 | 26.52 | |||||||
| Long Term Debt | 8.63 | 18.02 | 23.59 | |||||||
| Short Term Debt | 1.24 | 7.30 | 2.92 | |||||||
| Trade Payables | 4.32 | 6.92 | 13.79 | |||||||
| Others Liabilities ⓘ | 6.27 | 8.29 | 8.96 | |||||||
| Total Liabilities ⓘ | 36.84 | 58.72 | 74.14 | |||||||
Fixed Assets | ||||||||||
| Gross Block | 30.33 | 56.92 | 60.14 | |||||||
| Accumulated Depreciation | 13.09 | 14.41 | 16.66 | |||||||
| Net Fixed Assetsⓘ | 17.23 | 42.50 | 43.48 | |||||||
| CWIP ⓘ | 4.02 | 0 | 0 | |||||||
| Investmentsⓘ | 0 | 0 | 0 | |||||||
| Inventories | 3.05 | 6.33 | 9.10 | |||||||
| Trade Receivables | 8.42 | 5.08 | 15.37 | |||||||
| Cash Equivalents | 0.01 | 0.01 | 1.47 | |||||||
| Others Assetsⓘ | 4.10 | 4.81 | 4.72 | |||||||
| Total Assets ⓘ | 36.84 | 58.72 | 74.14 | |||||||
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 0.49 | 6.24 | 1.52 |
| PBT ⓘ | 3.80 | 2.55 | 4.05 |
| Adjustment ⓘ | 2.14 | 2.09 | 4.49 |
| Changes in Working Capital ⓘ | -5.45 | 1.6 | -7.03 |
| Tax Paid ⓘ | 0 | 0 | 0 |
| Cash Flow From Investing Activity ⓘ | -5.78 | -22.67 | -3.15 |
| Capex | -5.79 | -22.74 | -3.22 |
| Net Investments | 0 | 0 | 0 |
| Others ⓘ | 0.01 | 0.07 | 0.07 |
| Cash Flow From Financing Activityⓘ | 5.20 | 16.43 | 3.09 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 3.65 |
| Net Proceeds from Borrowing ⓘ | 3.23 | 9.39 | 5.58 |
| Interest Paid ⓘ | -0.51 | -0.55 | -2.11 |
| Dividend Paid ⓘ | 0 | 0 | 0 |
| Others ⓘ | 2.48 | 7.60 | -4.02 |
| Net Cash Flow ⓘ | -0.09 | -0.01 | 1.46 |
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 20.47 | 10.67 | 14.07 | |||||||
| ROCE (%) | 15.52 | 8.21 | 12.05 | |||||||
| Asset Turnover Ratio | 1.22 | 0.83 | 0.81 | |||||||
| PAT to CFO Conversion(x) | 0.15 | 3.39 | 0.5 | Working Capital Days | ||||||
| Receivable Days | 68 | 62 | 69 | |||||||
| Inventory Days | 25 | 43 | 52 | |||||||
| Payable Days | 59 | 98 | 106 | |||||||
Onyx Biotec Limited was incorporated on May 13, 2005 as a private limited company as ‘Onyx Biotec Private Limited’, under the Companies Act, 1956, pursuant to a certificate of incorporation dated May 13, 2005 issued by the Registrar of Companies, Punjab, H.P. & Chandigarh. Further, the company was converted into a public limited company pursuant to a resolution passed by its Board of Directors in its meeting held on May 1, 2024, and by the Shareholders in an Extraordinary General Meeting held on May 27, 2024 and consequently the name of the company was changed to ‘Onyx Biotec Limited’ and a fresh certificate of incorporation dated July 23, 2024 was issued by the Registrar of Companies, Central Processing Centre.
The company started its operation in pharmaceutical industry with sterile water for injections in the year 2010. Since then, the company has been associated with the healthcare segment and offering Sterile Pharmaceutical products and has become a prominent supplier of sterile products to major corporations, which includes the top pharma companies at pan India level. It is committed to provide high-quality products at affordable price. Also, the company manufactures Sterile Water for Injections, and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas.
Its products are being processed and manufactured in accordance with best Food and Drug Administration (FDA) practices available globally. Its system and product are tested constantly at each level to ensure international standards of quality in-house and FDA Certified Laboratories. Its core business is focused on providing end-to-end product development and manufacturing solutions to its clients. Its service also include preparation and filing of regulatory dossiers in the Indian and global markets. Its manufacturing units are equipped with Modern Equipment, ensures Quality Control and follows Sustainable Practices. Its manufacturing units have been accredited by global regulatory agency i.e. World Health Organization Good Manufacturing Practice (WHO-GMP).
Business area of the company
The company is engaged in the business of Manufacturing of Pharmaceutical Products such as sterile water ampoule, dry injection, dry syrup etc.
Products of the company
History and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
